Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio (ANVS) will give three presentations at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 16–19, 2026.
The program includes an oral presentation on investigational buntanetap’s mechanism and posters on its pivotal early Alzheimer’s study design and baseline characteristics, and artificial intelligence for predicting drug passage across the blood–brain barrier. Alexander Morin will deliver the oral presentation on November 19; both posters will be displayed November 16–17, with Cheng Fang presenting the trial-design poster. Annovis expects a pivotal data readout in early 2027 and is preparing for a New Drug Application.
Annovis Bio (ANVS) has partnered with Weave Bio’s AI-powered regulatory platform to prepare the planned NDA for buntanetap in Alzheimer’s disease.
Under the collaboration, Annovis will use Weave to draft, review and manage NDA documents while its internal regulatory and clinical teams retain full responsibility for content, verification and final FDA submissions. The company aims to have most of the NDA assembled before a 6‑month top-line data readout from its pivotal Phase 3 AD trial, which will form the basis of the filing. The Phase 3 study (NCT06709014) has completed enrollment with 862 biomarker-confirmed patients, above the original target of 760. Annovis targets database lock for the 6‑month treatment period in December 2026, followed by a top-line symptomatic data announcement in March 2027. Annovis and Weave state that their approach aligns with FDA guidance on AI use in regulatory decision-making issued in January 2025.
Annovis (NYSE: ANVS) will host a corporate update webinar with live Q&A on Wednesday, September 2, 2026, at 4:00 p.m. EDT, presented by Founder, President and CEO Maria Maccecchini, Ph.D.. The event will cover recent progress, clinical programs, and upcoming milestones for buntanetap in Alzheimer’s and Parkinson’s disease.
Annovis (NYSE: ANVS) reported second quarter 2026 results and clinical progress for buntanetap in Alzheimer’s and Parkinson’s disease. The pivotal Phase 3 early Alzheimer’s trial is now fully enrolled with 850 patients, above the original 760 target, with 6‑month top-line data expected in Q1 2027 and 18‑month data a year later.
An Alzheimer’s open‑label extension is planned to start in October 2026, while the Parkinson’s open‑label extension has enrolled 266 of a planned 500 patients across 26 US sites. Cash and equivalents were $18.7 million on June 30, 2026. Q2 research and development expenses rose to $12.0 million and general and administrative expenses to $2.4 million, driving a quarterly net loss of $14.8 million, or $0.40 per share. Annovis also promoted Cheng Fang, Ph.D., to Chief Scientific Officer and will host a corporate update webinar on September 2, 2026.
Annovis Bio (NYSE:ANVS) completed full enrollment in its pivotal Phase 3 trial of oral buntanetap for early Alzheimer’s disease, enrolling 850 pTau217-positive patients across 83 US sites.
The dual-design study targets 6‑month symptomatic and 18‑month disease‑modifying readouts, with top-line data expected in Q1 2027 and Q1 2028 and planned NDA submissions after each.
Annovis (NYSE: ANVS) promoted Cheng Fang, Ph.D., to Chief Scientific Officer. Fang, formerly Senior VP of R&D, will lead scientific strategy and research operations for the company’s Alzheimer’s and Parkinson’s programs.
The move comes as Annovis advances its oral therapy buntanetap toward Phase 3 Alzheimer’s top-line data and a potential NDA submission.
Annovis Bio (NYSE: ANVS) announced it has regained compliance with NYSE continued listing standards. The NYSE had notified the company on March 26, 2025 that its average global market cap and stockholders' equity were each below $50 million.
After NYSE accepted an 18‑month cure plan on June 19, 2025, Annovis executed corrective actions that raised both metrics above required thresholds within 12 months. NYSE has confirmed full compliance, and ANVS shares will remain listed as the company focuses on pivotal Phase 3 Alzheimer’s data and regulatory submissions.
Annovis (NYSE: ANVS) priced an underwritten public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares at a combined price of $1.90 per share and warrant.
Gross proceeds are expected to be about $15.0 million, mainly funding buntanetap Phase 3 programs in AD and PD.
Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together. All securities are offered by the company, with Canaccord Genuity as sole bookrunner.
Net proceeds are expected to fund Phase 3 development of buntanetap for Alzheimer’s disease, plus working capital and general corporate purposes. The offering’s completion, size and terms remain subject to market and other conditions.
Annovis (NYSE: ANVS) reported first quarter 2026 updates on buntanetap for Alzheimer's and Parkinson's and its financial position.
The Phase 3 AD trial is 85% enrolled with positive 6‑month DSMB safety review, the PD OLE study is 40% enrolled, key publications and a new U.S. patent were issued, and cash totaled $14.2 million at March 31, 2026.